Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Overview | 12 | 1 |
| Therapeutics Development | 13 | 6 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Products under Development by Stage of Development | 13 | 1 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Products under Development by Therapy Area | 14 | 1 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Products under Development by Indication | 15 | 4 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Pipeline Products Glance | 19 | 3 |
| Late Stage Products | 19 | 1 |
| Early Stage Products | 20 | 1 |
| Unknown Stage Products | 21 | 1 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Products under Development by Companies | 22 | 16 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Products under Development by Universities/Institutes | 38 | 2 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Therapeutics Assessment | 40 | 7 |
| Assessment by Monotherapy/Combination Products | 40 | 1 |
| Assessment by Mechanism of Action | 41 | 2 |
| Assessment by Route of Administration | 43 | 2 |
| Assessment by Molecule Type | 45 | 2 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Companies Involved in Therapeutics Development | 47 | 37 |
| Aduro BioTech, Inc. | 47 | 1 |
| Agenus, Inc. | 48 | 1 |
| Aurigene Discovery Technologies Limited | 49 | 1 |
| BeiGene, Ltd. | 50 | 1 |
| Beijing Hanmi Pharmaceutical Co., Ltd. | 51 | 1 |
| BIOCAD | 52 | 1 |
| Cellular Biomedicine Group, Inc. | 53 | 1 |
| CytomX Therapeutics, Inc. | 54 | 1 |
| Eli Lilly and Company | 55 | 1 |
| Enumeral Biomedical Holdings, Inc. | 56 | 1 |
| Immunovo BV | 57 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 58 | 1 |
| Jounce Therapeutics, Inc. | 59 | 1 |
| Les Laboratoires Servier SAS | 60 | 1 |
| MacroGenics, Inc. | 61 | 1 |
| MD Biosciences GmbH | 62 | 1 |
| MedImmune, LLC | 63 | 1 |
| Merck &Co., Inc. | 64 | 2 |
| Molecular Partners AG | 66 | 1 |
| Novartis AG | 67 | 1 |
| Ono Pharmaceutical Co., Ltd. | 68 | 4 |
| Pfizer Inc. | 72 | 1 |
| PharmaEssentia Corporation | 73 | 1 |
| Pieris Pharmaceuticals Inc | 74 | 1 |
| Regeneron Pharmaceuticals Inc | 75 | 1 |
| Sutro Biopharma, Inc. | 76 | 1 |
| Symphogen A/S | 77 | 1 |
| Tasly Pharmaceutical Group Co., Ltd. | 78 | 1 |
| Tesaro, Inc. | 79 | 1 |
| Theravectys SA | 80 | 1 |
| Tikcro Technologies, Ltd. | 81 | 1 |
| Vyriad | 82 | 1 |
| Xencor, Inc. | 83 | 1 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Drug Profiles | 84 | 118 |
| AM-0001 Drug Profile | 84 | 1 |
| AMP-224 Drug Profile | 85 | 2 |
| Anti-PD1 Monoclonal Antibody + Cellular Immunotherapy for Glioblastoma Drug Profile | 87 | 1 |
| AUR-012 Drug Profile | 88 | 1 |
| BGB-108 Drug Profile | 89 | 1 |
| BGBA-317 Drug Profile | 90 | 1 |
| Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor Drug Profile | 91 | 1 |
| Drug to Inhibit PD-1, Gal-9 and TIM-3 for Solid Tumor Drug Profile | 92 | 1 |
| durvalumab + MEDI-0680 Drug Profile | 93 | 1 |
| ENUM-003 Drug Profile | 94 | 2 |
| ENUM-388D4 Drug Profile | 96 | 1 |
| GXP-2 Drug Profile | 97 | 1 |
| IBI-308 Drug Profile | 98 | 1 |
| JS-001 Drug Profile | 99 | 1 |
| MD-402 Drug Profile | 100 | 1 |
| mDX-400 Drug Profile | 101 | 1 |
| MEDI-0680 Drug Profile | 102 | 1 |
| MGD-013 Drug Profile | 103 | 1 |
| Monoclonal Antibodies to Antagonize PD-1 for Oncology Drug Profile | 104 | 1 |
| Monoclonal Antibodies to Antagonize PD-1 for Oncology Drug Profile | 105 | 1 |
| Monoclonal Antibodies to Antagonize PD1 for Metastatic Melanoma and Metastatic Lung Cancer Drug Profile | 106 | 1 |
| Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology Drug Profile | 107 | 1 |
| Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections Drug Profile | 108 | 1 |
| Monoclonal Antibody to Antagonize PD-1 for Autoimmune Disorders and Oncology Drug Profile | 109 | 1 |
| Monoclonal Antibody to Antagonize PD-1 for Non-Small Cell Lung Cancer Drug Profile | 110 | 1 |
| Monoclonal Antibody to Antagonize PD-1 for Oncology Drug Profile | 111 | 1 |
| Monoclonal Antibody to Antagonize PD-1 for Oncology Drug Profile | 112 | 1 |
| Monoclonal Antibody to Antagonize PD-1 for Oncology Drug Profile | 113 | 1 |
| Monoclonal Antibody to Antagonize PD1 for Oncology Drug Profile | 114 | 1 |
| Monoclonal Antibody to Antagonize PD1 for Oncology Drug Profile | 115 | 1 |
| Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology Drug Profile | 116 | 1 |
| Monoclonal Antibody to Inhibit PD-1 and TIM3 for Oncology Drug Profile | 117 | 1 |
| Monoclonal Antibody to Inhibit PD-1 for Cancer Drug Profile | 118 | 1 |
| Monoclonal Antibody to Inhibit PD-1 for HIV Drug Profile | 119 | 1 |
| Monoclonal Antibody to Inhibit PD-1 for Oncology Drug Profile | 120 | 1 |
| Monocloncal Antibody to Inhibit PD-1 for Oncology Drug Profile | 121 | 1 |
| nivolumab Drug Profile | 122 | 30 |
| Oncolytic Virus to Activate IFNb for Head and Neck Cancer and Lewis Lung Cancer Drug Profile | 152 | 1 |
| pazopanib hydrochloride + pembrolizumab Drug Profile | 153 | 1 |
| PD-1 Antagonist + ropeginterferon alfa-2b Drug Profile | 154 | 1 |
| PDR-001 Drug Profile | 155 | 1 |
| PEGMP-7 Drug Profile | 156 | 1 |
| pembrolizumab Drug Profile | 157 | 32 |
| PF-06801591 Drug Profile | 189 | 1 |
| PRS-332 Drug Profile | 190 | 1 |
| Recombinant Protein to Inhibit VEGF-A and PD1 for Solid Tumor and Hematological Malignancies Drug Profile | 191 | 1 |
| REGN-2810 Drug Profile | 192 | 2 |
| SHR-1210 Drug Profile | 194 | 1 |
| SNPD-07 Drug Profile | 195 | 1 |
| STIA-1110 Drug Profile | 196 | 1 |
| TSR-042 Drug Profile | 197 | 1 |
| Vaccine to Target CD274 and CD279 for Bladder Cancer Drug Profile | 198 | 1 |
| Vaccine to Target CD274 and CD279 for Colorectal Cancer Drug Profile | 199 | 1 |
| Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma Drug Profile | 200 | 1 |
| XmAb-20717 Drug Profile | 201 | 1 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Dormant Projects | 202 | 1 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Discontinued Products | 203 | 1 |
| Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Featured News &Press Releases | 204 | 16 |
| Aug 09, 2016: Esophageal &Lung Institute of Allgheny Health Network Launches Study of Immunotherapy Drug For Advanced Esophageal Cancer | 204 | 1 |
| Aug 09, 2016: Influence of Clinical Results from CheckMate-026, a Phase III Study of Opdivo (nivolumab) in Treatment-Na ve Patients with Advanced Non-Small Cell Lung Cancer | 205 | 1 |
| Aug 08, 2016: SMC U-turn offers lifeline to Scottish skin cancer patients | 206 | 1 |
| Aug 05, 2016: Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Na ve Patients with Advanced Non-Small Cell Lung Cancer | 207 | 1 |
| Aug 05, 2016: Bristol-Myers Squibb Statement on Top-Line Results from CheckMate -026 | 207 | 1 |
| Aug 05, 2016: FDA Approves Merck s KEYTRUDA (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy | 208 | 2 |
| Aug 04, 2016: Gene expression profile may ID renal cell carcinoma pts unlikely to benefit from nivolumab | 210 | 1 |
| Aug 03, 2016: NICE Issues Technology Appraisal Guidance for Nivolumab in Combination With Ipilimumab for Advanced Melanoma | 211 | 1 |
| Aug 03, 2016: Agilent Technologies Announces Availability of New Companion Diagnostic in Europe | 212 | 1 |
| Aug 02, 2016: Merck s KEYTRUDA (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 | 213 | 1 |
| Jul 27, 2016: ONO Submits Supplemental Application of OPDIVO (Nivolumab) for Recurrent or Metastatic Head and Neck Cancer for a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan | 213 | 1 |
| Jul 21, 2016: Sarc Researchers Report Immunotherapy Effective in Selected Sarcoma Subtypes | 214 | 1 |
| Jul 18, 2016: Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | 215 | 2 |
| Jul 13, 2016: Study finds first evidence that PD-1 antibody could help men with metastatic prostate cancer | 217 | 1 |
| Jul 13, 2016: UCLA study unlocks key mechanisms that determine acquired resistance to immunotherapy in advanced melanoma | 218 | 2 |
| Appendix | 220 | 2 |
| Methodology | 220 | 1 |
| Coverage | 220 | 1 |
| Secondary Research | 220 | 1 |
| Primary Research | 220 | 1 |
| Expert Panel Validation | 220 | 1 |
| Contact Us | 220 | 1 |
| Disclaimer | 221 | 1 |
